« Return to News | R&D Trends

Cenix BioScience, Debiopharm Group to identify predictive biomarkers

Wednesday, May 29, 2013 10:47 AM

Cenix BioScience, a preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a global Swiss biopharmaceutical group of companies focused on prescription drugs that target unmet medical needs, including oncology and companion diagnostics, have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

Cenix will apply its expertise in combining high throughput screening with high content assays in cultured human cells, to identify predictive biomarkers for Debiopharm preclinical oncology candidates. Multi-parametric microscopy-based readouts established by Cenix using the Definiens XD image analysis platform will be used in a range of human cancer cell models to identify genes and pathways that either enhance or suppress the drug's therapeutic effects.

"We are very excited to launch this new relationship with Debiopharm, extending their repertoire with what we consider to be some of the most strategically powerful cell-based screening paradigms developed to date," said Dr. Christophe Echeverri, CEO/CSO of Cenix BioScience.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.